TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

CLINTEC

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

CLINTEC

ST13

US500000079100249

Classe

35, 41, 42, 45

Pedido

79100249

Registro

4162941

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

55

Atualização mais recente

17/03/2024

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

35, 41, 42, 45

Data de depósito

08/03/2011

Data de registro

26/06/2012

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

24/05/2023

Última transação

08/07/2023

Escritório responsável

United States Patent and Trademark Office

Código da situação

706

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

99

Localização do titular

Glasgow, GB

Examinador

CARROLL, DORITT

Unidade examinadora

M70

Localização atual

GENERIC WEB UPDATE

Titulares e representantes

Titulares

Clintec International Limited
Clintec International Limited

Representantes

Arlene D. Hanks Moore & Van Allen PLLC

Classificação técnica

Classes Nice

Classe 35Classe 41Classe 42Classe 45

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 35

Business consultation in the field of clinical research [ and pharmaceutical commercialisation; ] compilation and systemization of information into computer databases; database management for others of a database comprised of data collected for clinical and biostatistics research purposes; personnel recruitment and placement in the field of clinical research; compilation and provision of statistical analysis reports; [ statistical consulting services for pharmaceutical, biotechnology and medical device industries for business purposes; ] creation and implementation of statistical analysis plans for business purposes; writing of business reports; business strategic planning [ ; market research, assessment, analysis and evaluation; business feasibility studies ]

Classe 41

[ Educational and ] training services in the field of clinical trials regulation and clinical research; [ Providing, arranging and conducting workshops, seminars, and educational conferences in the field of clinical trials regulation and clinical research; ] training in data capture and management; training [ and education ] in regulatory affairs; [ Providing, arranging and conducting training and educational classes, workshops, seminars, and education conferences in medical writing; providing, arranging and conducting training and educational classes, workshops, seminars, and education conferences training and education in quality control, auditing and inspection; writing of texts; ] training services, namely, training of clinical and scientific researchers to conduct clinical research and drug development studies

Classe 42

Scientific and technological services and research and design in the field of clinical trials and clinical research; industrial analysis and research services in the field of clinical trials and clinical research; clinical research services, namely, implementation of clinical studies and providing reports thereon; [ management of scientific research projects; conducting clinical research projects in the field of clinical trials and clinical research; ] conducting and monitoring clinical trials [ ; quality audit services, quality assurance consultancy, quality control testing in the field of quality control for others; technical inspection services, namely, inspection of clinical data, clinical procedure, clinical process, clinical database, and clinical reports for others; pharmaceutical product evaluation; design and conducting of technical feasibility studies; drug development services; quality management of drug development; preparation of reports in relation to clinical trials and clinical research, including preparation of reports on management of scientific research projects, clinical research projects, clinical trials, audits, pharmaceutical product evaluations, drug development and pharmaceutical product evaluations ]

Classe 45

[ Advisory and consultancy services relating to regulatory affairs in the field of clinical trials, clinical research and drug development; ] advisory and consultancy services relating to national and international regulation of clinical trials and drug development

Publicações

Histórico de despachos e eventos da marca no USPTO.

55 publicações encontradas

INNP

PARTIAL INVALIDATION PROCESSED BY THE IB

17/03/2024

INPS

PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB

03/02/2024

INPC

INVALIDATION PROCESSED

02/02/2024

INPR

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED

24/01/2024

NA71

NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED

24/05/2023

71AG

REGISTERED-SEC.71 ACCEPTED

24/05/2023

EROP

TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED

22/05/2023

PR71

POST REGISTRATION ACTION MAILED - SEC.71

22/12/2022

XXXX

POST REGISTRATION ACTION CORRECTION

22/12/2022

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

22/12/2022

ES71

TEAS SECTION 71 RECEIVED

29/06/2022

REM4

COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED

26/06/2021

RNWL

INTERNATIONAL REGISTRATION RENEWED

25/03/2021

NREP

NEW REPRESENTATIVE AT IB RECEIVED

22/01/2021

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

15/01/2019

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

15/01/2019

NA75

NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED

02/12/2017

C75A

REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.

02/12/2017

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

01/12/2017

ES75

TEAS SECTION 71 & 15 RECEIVED

03/11/2017

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

26/06/2017

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

28/09/2014

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

28/09/2014

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

06/08/2013

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

06/08/2013

GPNX

NOTIFICATION PROCESSED BY IB

02/12/2012

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

15/10/2012

FICS

FINAL DISPOSITION NOTICE SENT TO IB

26/09/2012

FIMP

FINAL DISPOSITION PROCESSED

26/09/2012

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

26/09/2012

R.PR

REGISTERED-PRINCIPAL REGISTER

26/06/2012

CORR

CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED

17/05/2012

CRCV

CORRECTION TRANSACTION RECEIVED FROM IB

11/05/2012

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

10/04/2012

PUBO

PUBLISHED FOR OPPOSITION

10/04/2012

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

04/04/2012

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

04/04/2012

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

21/03/2012

PREV

LAW OFFICE PUBLICATION REVIEW COMPLETED

05/03/2012

ALIE

ASSIGNED TO LIE

29/02/2012

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

11/02/2012

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

10/02/2012

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

10/02/2012

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

10/02/2012

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

18/10/2011

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

18/10/2011

RFNP

REFUSAL PROCESSED BY IB

27/08/2011

MAFR

APPLICATION FILING RECEIPT MAILED

11/08/2011

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

10/08/2011

RFRR

REFUSAL PROCESSED BY MPU

10/08/2011

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

10/08/2011

CNRT

NON-FINAL ACTION WRITTEN

09/08/2011

DOCK

ASSIGNED TO EXAMINER

08/08/2011

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

07/08/2011

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

04/08/2011

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace CLINTEC ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.